Navigation

P15

Poster
Cardiovascular benefits of new antidiabetic drug classes: a network meta-analysis

B. M. Y. Cheung1, Y. Fei1, M. F. Tsoi1 (1Hong Kong HK)


Aim: New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.

 

Method: We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes using major adverse cardiovascular events (MACE) and mortality as endpoints. Network meta-analysis was performed using random-effects model in R.

 

Results: 13 CVOTs with altogether 116746 patients were included (fig. 1). GLP-1 RAs and SGLT-2 inhibitors significantly lowered the risk of MACE (OR 0.87, 95% CI 0.82-0.94 and 0.89, 0.82-0.97), all-cause mortality (0.90, 0.82-0.99 and 0.84, 0.76-0.93), heart failure (0.87, 0.82-0.93 and 0.70, 0.62-0.80), and renal composite outcome (0.85, 0.75-0.97 and 0.63, 0.55-0.72) when compared to placebo (fig. 2). GLP-1 RAs reduced nonfatal stroke (0.88, 0.77-0.99) while SGLT-2 inhibitors reduced cardiovascular mortality (0.83, 0.72-0.96). In contrast, DPP-4 inhibitors did not significantly alter the risk of these outcomes.

 

Conclusion: GLP-1 RAs and SGLT-2 inhibitors both reduce MACE, heart failure, renal composite outcome, and all-cause mortality when compared to placebo. DPP-4 inhibitors did not show any cardiovascular benefits. Our findings support using SGLT-2 inhibitors and GLP-1 RAs for diabetic patients with high cardiovascular risk.

Fig. 1
Fig. 1
Fig. 2
Fig. 2
    
        Array
(
    [id] => 7
    [abstract_id] => 42
    [session_id] => 1
    [pres_nbr] => P15
    [updated] => 
    [created] => 0000-00-00 00:00:00
    [abstract] => Array
        (
            [id] => 42
            [user_id] => 23
            [contact_id] => 19
            [knr] => c1541c08
            [titel] => Cardiovascular benefits of new antidiabetic drug classes: a network meta-analysis

            [text] => 

Aim: New antidiabetic drugs are required to be evaluated in cardiovascular outcome trials (CVOTs). Few of these are direct comparisons between new drugs, so we performed a network meta-analysis to compare the new drug classes in terms of cardiovascular outcomes.

 

Method: We searched for CVOTs involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose co-transporter 2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes using major adverse cardiovascular events (MACE) and mortality as endpoints. Network meta-analysis was performed using random-effects model in R.

 

Results: 13 CVOTs with altogether 116746 patients were included (fig. 1). GLP-1 RAs and SGLT-2 inhibitors significantly lowered the risk of MACE (OR 0.87, 95% CI 0.82-0.94 and 0.89, 0.82-0.97), all-cause mortality (0.90, 0.82-0.99 and 0.84, 0.76-0.93), heart failure (0.87, 0.82-0.93 and 0.70, 0.62-0.80), and renal composite outcome (0.85, 0.75-0.97 and 0.63, 0.55-0.72) when compared to placebo (fig. 2). GLP-1 RAs reduced nonfatal stroke (0.88, 0.77-0.99) while SGLT-2 inhibitors reduced cardiovascular mortality (0.83, 0.72-0.96). In contrast, DPP-4 inhibitors did not significantly alter the risk of these outcomes.

 

Conclusion: GLP-1 RAs and SGLT-2 inhibitors both reduce MACE, heart failure, renal composite outcome, and all-cause mortality when compared to placebo. DPP-4 inhibitors did not show any cardiovascular benefits. Our findings support using SGLT-2 inhibitors and GLP-1 RAs for diabetic patients with high cardiovascular risk.

[pres_form] => [bio_presenting_author] => [german_presentation] => 0 [contact_complete] => 1 [authors_complete] => 1 [abstract_complete] => 1 [images_complete] => 1 [confirmation_complete] => 1 [updated] => [created] => 2019-03-01 01:35:06 [sprache] => en [atherosclerosis_basic] => 0 [atherosclerosis_clinical] => 0 [heartfailure_basic] => 0 [heartfailure_clinical] => 0 [arrhythmia_basic] => 0 [arrhythmia_clinical] => 0 [hypertension_diabetes_dyslipidemia] => 1 [preventive_medicine] => 0 [contact] => stdClass Object ( [id] => 19 [user_id] => 23 [anrede] => 1 [akad_titel] => 5 [vorname] => Bernard [name] => Cheung [institution] => University of Hong Kong [department] => Department of Medicine [adresszeile1] => Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, [adresszeile2] => [adresszeile3] => [plz] => 000 [ort] => Hong Kong [land] => HK [email] => mycheung@hku.hk [telefon] => [lang] => [updated] => [created] => 0000-00-00 00:00:00 ) [authors] => Array ( [0] => stdClass Object ( [id] => 92 [abstract_id] => 42 [vorname] => Bernard M Y [name] => Cheung [qualification] => [institution] => University of Hong Kong [ort] => Hong Kong [land] => HK [sort] => 1 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) [1] => stdClass Object ( [id] => 93 [abstract_id] => 42 [vorname] => Yue [name] => Fei [qualification] => [institution] => University of Hong Kong [ort] => Hong Kong [land] => HK [sort] => 2 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) [2] => stdClass Object ( [id] => 96 [abstract_id] => 42 [vorname] => Man Fung [name] => Tsoi [qualification] => [institution] => University of Hong Kong [ort] => Hong Kong [land] => HK [sort] => 3 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) ) [files] => Array ( [0] => stdClass Object ( [id] => 14 [abstract_id] => 42 [filename] => 6e6731d25f73318b766b4a1b1b778743.png [description] => Fig. 1 [sort] => 0 [updated] => [created] => 0000-00-00 00:00:00 ) [1] => stdClass Object ( [id] => 15 [abstract_id] => 42 [filename] => cd14427a8fd0270feb0f1ea5573c4123.png [description] => Fig. 2 [sort] => 0 [updated] => [created] => 0000-00-00 00:00:00 ) ) [main_author] => stdClass Object ( [id] => 92 [abstract_id] => 42 [vorname] => Bernard M Y [name] => Cheung [qualification] => [institution] => University of Hong Kong [ort] => Hong Kong [land] => HK [sort] => 1 [is_presenting_author] => [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_contact] =>
Bernard Cheung
HK-000 Hong Kong
mycheung@hku.hk ) [session] => stdClass Object ( [id] => 1 [name] => Poster [date] => 2019-05-09 [start] => 00:00:00 [end] => 00:00:00 [abbr] => P [updated] => [created] => 0000-00-00 00:00:00 ) [formatted_authors] => B. M. Y. Cheung1, Y. Fei1, M. F. Tsoi1 (1Hong Kong HK) [detail_url] => https://www.iscp2019.com/abstracts/presentation/7 )